MedPath

Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer

Conditions
Luminal A
Immune Microenvironment
Lymph Node Metastases
Interventions
Other: no intervention
Registration Number
NCT04322331
Lead Sponsor
Peking University People's Hospital
Brief Summary

Luminal type A breast cancer is a type with good clinical prognosis, and the proportion of lymph node metastasis is low, but a small number of patients have more lymph node metastasis when the primary tumor is very small, and the survival is poor, suggesting that this part of Luminal A breast cancer has the different expression of some genes from that of general Luminal A breast cancer, which affects tumor invasion and participates in the occurrence of tumor metastasis. But the mechanism is not clear, especially in the current tumor microenvironment and immune related mechanisms.We want to investigated the relationship of the transcriptional tumor immune microenvironment with early lymph node metastasis among Luminal A type breast cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • invasive breast cancer with Luminal A type;T1 with positive lymph node or T2/T3 with negative lymph node
Exclusion Criteria
  • Missing specimen

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
T1N+no interventionT1 tumor with positive lymph node,N1/N2/N3
T2/T3N0no interventionT2/T3 tumor with negative lymph node
Primary Outcome Measures
NameTimeMethod
Transcriptional Characterization2020-12

the relationship of the transcriptional tumor immune microenvironment with lymph node metastases in Luminal A breast tumor;Differences in RNA copy numbers of different genes (using IO Panel) between the two groups of patients

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Peking university people's hospital

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath